8-K: Perrigo Reports Strong Q1 2025 Results Driven by Infant Formula Recovery, Widens Net Sales Outlook

Perrigo's Q1 2025 results show strong adjusted EPS growth and margin expansion, fueled by the recovery of the infant formula business, while the company widens its net sales target ranges for 2025 due to macroeconomic uncertainty.

Summary

• Perrigo Company plc reported its first quarter 2025 financial results, showcasing advancements in its 'Three-S' Plan.
• Net sales reached $1.04 billion, a 3.5% decrease primarily due to divested businesses and currency translation.
• Organic net sales decreased by 0.4%, but excluding specific factors, organic net sales grew by 1.8%.
• The Consumer Self-Care International (CSCI) segment saw a 3.4% decrease in net sales to $423 million, but organic net sales grew by 4.5%.
• Consumer Self-Care Americas (CSCA) net sales were down 3.6% to $621 million.
• GAAP gross margin increased by 450 basis points to 37.6%, while adjusted gross margin expanded by 440 basis points to 41.0%.
• Reported operating income was $47 million, compared to a loss of $(55) million in the prior year quarter.
• Adjusted operating income increased by 57.6% to $147 million.
• Reported EPS was breakeven, while adjusted EPS increased by 106.9% to $0.60.
• The company has widened its fiscal 2025 outlook for reported net sales growth to 0% to 3% and organic net sales growth to 1.5% to 4.5%, while reaffirming all other 2025 financial targets.
• Project Energize is expected to deliver annualized pre-tax savings in the range of $140 million to $170 million by the end of 2026.

Sentiment

Score: 7

Explanation: The sentiment is positive due to strong EPS growth and margin expansion, driven by the infant formula recovery and cost-saving initiatives. However, macroeconomic uncertainties and widened net sales outlook temper the overall optimism.

Positives

• Infant formula business recovery led to net sales growth in the Nutrition category of 16%.
• Global brands delivered organic growth of +5.9%, excluding the prior year benefit from retailer stocking due to the launch of Opill.
• Adjusted gross margin expanded 440 basis points to 41.0%.
• Adjusted operating income increased $54 million, or 57.6%, to $147 million.
• Adjusted diluted EPS increased $0.31, or 106.9%, per share, to $0.60.
• Project Energize has achieved gross annual savings of approximately $159 million with reinvestment of $20 million.
• The company is the largest U.S. manufacturer of OTC self-care products by volume.

Negatives

• Net sales decreased 3.5% due to unfavorable impacts from divested businesses, exited product lines, and currency translation.
• Organic net sales decreased 0.4% due to net lost distribution of lower margin products in U.S. Store Brand, the lack of a prior year benefit in the Women's Health category, and lower net sales in the Digestive Health category.
• CSCA net sales were down 3.6% compared to the prior year quarter.
• First quarter 2025 cash from operations was a loss of $(65) million compared to a loss of $(1) million in the prior year quarter.
• CSCI net sales of $423 million declined 3.4% compared to the prior year quarter.

Risks

• Macroeconomic uncertainty, including tariffs and consumer behavior, present new challenges.
• Tariffs are expected to increase the global cost of goods sold, primarily in Oral Care in CSCA.
• The company estimates a gross increase to global cost of goods sold in 2025 beginning in the fourth quarter of more than 1%, or approximately $30 million to $40 million, and approximately 5.5%, or approximately $145 million to $155 million, on a full-year basis.
• Consumer prices are likely to rise.

Future Outlook

The company widens its fiscal 2025 outlook for reported net sales growth to 0% to 3% and organic net sales growth to 1.5% to 4.5%, while reaffirming all other 2025 financial targets, including adjusted EPS.

Management Comments

• President and CEO Patrick Lockwood-Taylor commented, 'We advanced our 'Three-S' Plan to Stabilize, Streamline, and Strengthen Perrigo as Stabilization and recovery efforts in our infant formula business led to net sales growth in the Nutrition category of 16%.'
• Lockwood-Taylor concluded, 'While macroenvironment uncertainty, including tariffs and consumer behavior, present new challenges, we have proactively engaged in extensive scenario planning to mitigate these impacts.'

Industry Context

Perrigo, as a leading provider of consumer self-care products, is navigating macroeconomic challenges such as tariffs and consumer behavior shifts. The company's focus on store brand and value brand offerings positions it well to benefit from consumers seeking more affordable options. The recovery in the infant formula market is a key driver for growth, reflecting broader trends in the nutrition category.

Comparison to Industry Standards

• Perrigo's adjusted gross margin of 41.0% is comparable to other consumer healthcare companies, such as Haleon (adjusted operating margin around 23%) and Church & Dwight (gross margin around 43%).
• The company's focus on cost reduction through Project Energize aligns with industry trends of streamlining operations to improve profitability.
• Perrigo's emphasis on U.S.-based manufacturing provides a competitive advantage in the face of increasing tariffs, similar to strategies employed by other companies to mitigate supply chain risks.

Stakeholder Impact

• Shareholders will benefit from the increased profitability and EPS growth.
• Consumers may face higher prices due to tariffs, but Perrigo's store brand offerings could provide more affordable options.
• Employees may be affected by Project Energize, which aims to streamline operations and increase organizational agility.

Next Steps

• The company plans to offset the impact of tariffs through strategic pricing actions, insourcing to U.S.-based manufacturing facilities, and other supply chain actions.
• Investments and innovations to Strengthen the business through our 'High-Grow' brands remain on track to derive benefits in 2026.
• Management will host an earnings conference call to discuss its first quarter 2025 financial results beginning at 08:30 A.M. (EST) Wednesday, May 7, 2025.

Key Dates

Keywords

Perrigo, financial results, consumer self-care, infant formula, net sales, EPS, gross margin, operating income, Project Energize, tariffs